CHEMOTHERAPY NOV. 1990

Similar documents
CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation

CHEMOTHERAPY APR. 1984

CHEMOTHERAPY



VOL. 34 S-2 CHEMOTHERAPY


Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX



Fig. 2 Body weight curves rats treated orally with DL-8280 for 4 weeks


CHEMOTHERAPY DEC.1992

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

VOL. 36 S-3 CHEMOTHERAPY 437


CHEMOTHERAPY JUNE 1988 ( })-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-l-piperaziny1) 4-oxo-3-quinolinecarboxylic acid hydrochloride Fig. 1. Chemica

日本消化器外科学会雑誌第31巻第7号

Fig. 1 A: Effects of intramuscular injection of glucagon on the blood glucose levels (changes from basal, ƒ BG) as compared with effects of scopolamin

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

<95DB8C9288E397C389C88A E696E6462>

VOL. 19 NO. 5 CHEMOTHERAPY


VOL. 34 S-2 CHEMOTH8RAPY 913

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

日本消化器外科学会雑誌第25巻第11号

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

Table 1. Influence of food deprivation on gastric secretion and severity of ulceration in 18 hr pylorus ligated rats.

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09330)

320 Nippon Shokuhin Kagaku Kogaku Kaishi Vol. /., No.1, -,* -,/ (,**1) 8 * ** *** * ** *** E#ect of Superheated Steam Treatment on the Preservation an



CHEMOTHERAPY

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin


Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

Effects of Light and Soil Moisture Condition on the Growth of Seedlings for Quercus serrata and Quercus variabilis NISHIMURA, Naoyuki*, OTA, Takeshi**

1272 CHEMOTHERAPY MAR. 1975

...Q.....\1_4.ai

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

明海大学歯学雑誌　３７‐２／１．秦泉寺

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

2 94



106(18) 原 使 用 した 測 定 部 位 は 期 門 穴相 当部 位 の 表 皮 上 及 び 真 皮 下 と し, 表 皮上 で は 艾 柱 の 直 下 に 熱 電 対 先 端 を露 出 し固 定 した 真 皮 下 で は施 灸部 より10mm 下 方 を切 開 剥 離 し, 施 灸 部 直

qx


CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz

Fig. 1 Chemical structure of KW-1070

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

988 CHEMOTHERAPY NOV. 1971

VOL.39 S-3

Fig. 1. Experimental design

Fig. 1 Chemical structure of DL-8280

J. Soc. Cosmet. Chem. Japan. Vol. 22, No

Changes in Electrodermal Activity Associated with Candies and Chewing Gum Chewing Satoshi Beppu, Takeshi Morita*, Susumu Igarashi **, Kanichi Seto* an

VOL.40 S-1


(J. Yamashina Inst. Ornithol.), 25: 76-92, 1993 Breeding Biology of Dryocopus martius in Central Hokkaido Hirotomi Konishi*, Toshioki Suzuki*, Katsumi

小児感染免疫第25巻第2号

VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3

CHEMOTHERAPY FEB Table 1 Background of volunteers

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio

VOL.42 S-1

Fig. 1 Method of SRCA Table 1 Drug dose and treatment schedule in SRCA Table 2 Results of SRCA for renal cell carcinomas * Histological grading of the

実験的顎口虫症の研究 : 特に顎口虫の発育に及ぼす宿主及臓器の特異性に関する研究 : II ダイコクネズミ体内に於ける第3期幼虫の発育に及ぼすcortisoneの影響

Title 泌尿器科領域に於ける17-Ketosteroidの研究 17-Ketosteroidの臨床的研究 第 III 篇 : 尿 Author(s) 卜部, 敏入 Citation 泌尿器科紀要 (1958), 4(1): 3-31 Issue Date URL

Physical and Psychological Effects of Stressors in Female College Students Reizou Mita*1, Konosuke Tomabechi*1, Isao Yamaguchi*1, Naoko Soeno*1, Shuhe

Fig. 1. Structure of [methyl-14c]zonisamide

untitled

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Table 1 Components of corn dietary fibers

CHEMOTHERAPY JUNE 1986

CHEMOTHERAPY SEPT. 1991

VOL.27 CHEMOT S-1 HERAPY 185 に感 性 を示 して い たが,臨 床 的 に は無 効 で あ った 本 症 る 細 菌学 的 に も検 討 した が,起 炎菌 と考 え られ る細 菌 を 例 で は 基礎 疾 患 と して縦 隔 洞腫 瘍 が あ り,既 に 副 腎

Table 1 Characteristics of the study participants in Imari municipal hospital

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

J. Soc. Cosmet. Chem. Jpn. 7-chome, Edogawa-ku, Tokyo 132, Japan 2.1 J. Soc. Cosmet. Chem. Japan. Vol. 31, No

技術研究報告第２６号

..,,...,..,...,,.,....,,,.,.,,.,.,,,.,.,.,.,,.,,,.,,,,.,,, Becker., Becker,,,,,, Becker,.,,,,.,,.,.,,

324 Fig. 1. Thermal data recorder and sensor protector Fig. 2. Outline of animal room. Fig. 3. Distribution of sensors

CHEMOTHERAPY MAY. 1988

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study


56 CHEMOTHERAPY JAN Fig. 1 Effect of Mezlocillin on respiration, blood pressure and ECG in the rabbit

硫酸アルミニウムカリウムタンニン酸注射液（ALTA）による内痔核硬化療法後にフルニエ症候群をきたした1例　第65巻02号0075頁

VOL.27S-1 CHEMOTHERAPY 109 Klebsiella, Proteus, Pseudomonas Streptococcus Fig. 1 Concentration in blood and in CSF after intravenous drip infusion of

Fig. 1 Chemical structure of norfioxacin (AM-715)


Jan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis

2001 Received November 28, 2014 Current status and long-term changes of the physique and physical fitness of female university students Shiho Hiraku Y

Title 歯性病巣の関連する皮膚疾患におけるビオチンの効用 Author(s) 高橋, 愼一 ; 川島, 淳子 ; 森本, 光明 ; 山根, 源之 Journal, (): - URL Right Posted at the Inst

Fig.1 A location map for the continental ultradeep scientific drilling operations.

Transcription:

VOL.38 S-2 6, 8- Difluoro- 1-(2- fluoroethyl)- 1, 4- dihydro- 7-(4- methyl- 1- piperazinyl)- 4- oxo- 3- quinolinecarboxylic

CHEMOTHERAPY NOV. 1990

VOL.38 S-2 Fig. 1. Body weight changes of male rats treated orally with fleroxacin.

CHEMOTHERAPY NOV. 1990 Fig. 2. Food consumption changes of male rats treated orally with fleroxacin before mating. Fig. 3. Water consumption changes of male rats treated orally with fleroxacin before mating.

Fleroxacinの S-2 VOL.38 Table 1. 1) Mean } SD 2) Mean } * Significant SD (unit= difference Table 2. (unit= ラ ッ トに お け る 生 殖 試 験 Sexual organ weight of male rats treated 265 with fleroxacin g) g/100 from g BW) the control Histopathological (p<0.05) findings of reproductive organs in male rats treated with fleroxacin for 2.5 months * Significant difference from the control (p<0.05) 1) Including one dead animal after mating Fig. 4. Testis No of a male remarkable rat in changes. ~33 control Fig.5.Testisofamaleratinthe320mglkggroup. group. HE stain. Note:Atrophy There Several of seminiferous are few giant tubules. spermatids cells are or spermatozoa. Present. 66 HE stain

266 NOV.1990 CHEMOTHERAPY 目 に お け る剖 検 の 結 果,20mg/kg群 に肝 小 3.生 葉 明 瞭 と胃 幽 門 部 の 出血 斑 が 各1例,80mg/kg群 妊 娠20日 に卵巣 生 殖 能 力 試 験 の 結 果 をTable3に 水 腫1例 と盲 腸 の腫 大 が2例,320mg/kg群 では子宮水腫 殖能力 回 の 交 配 に よ り対 照 群 及 びfleroxacin各 と横 隔 膜 ヘ ル ニ アが 各1例 と盲腸 の腫 大 が10例 認 め られ ず れ も100%の た ま た,320mg/kg群 い て は 対 照 群 の100%に の 交 尾 未確 認 動 物 に盲 腸 の腫 大 が1例 認 め られ た Fig. 6. Epididymis No remarkable 320mg/kg群 of a male rat changes. ~ in control group. 33 Fig. HE stain. 7. 交 尾 が 認 め ら れ,妊 投 与 群 の 雌雄い 性 率 及 び妊 娠 率につ 対 し,20mg/kg群,80mg/kg群, で は そ れ ぞ れ91.7%,87.5%,83.3%を Epididymis of a male rat in the 320 in most 示 mg/kg group. Note: There are a few spermatozoa tubules. ~ Fig. 8. 示 し た 第1,2,3 Body weight changes of female rats treated of the 33 orally with fleroxacin. HE stain.

VOL.38 S-2 Fig. 9. Food consumption changes of female rats treated orally with fleroxacin. Fig. 10. Water consumption changes of female rats treated orally with fleroxacin.

CHEMOTHERAPY NOV. 1990 Table 3. Reproductive performance of rats treated with fleroxacin in the fertility study No.of unknown copulating rats 1) Mean }SD 2)(No.of copulating rats/ No.of mated rats) ~100 3)(No.of infertile copulating rats/ No.of mated rats) ~100 4)(No.of pregnant rats/ No.of copulating rats) ~100

VOL.38 S-2 Table 4. Effects of fleroxacin on pregnant rats * Significant difference from the control (p< 0.05) 1) Contain a delivery animal 2) Excluding newborn animals 3) Mean }SD Table 5. Effects of fleroxacin on the rat fetuses * Significant difference from the control (p< 0.05) 1) Excluding unknown copulation rats 2) Mean }SD

CHEMOTHERAPY NOV. 1990 1) HIRAI K, AOYAMA H, HOSAKA M, OOMORI Y, NIWATA Y, SUZUE S, IRIKVRA T: In vitro and in vivo antibacterial activity of AM- 833, a new quinolone derivative. Antimicrob Agents Chemother 29: 1059 ` 1066, 1986

VOL.38 S-2 FERTILITY STUDY ON FLEROXACIN IN RATS HIROSHI SUZUKI, TAKIO TAKAHASHI, YUKO SATO and YASUO ABE Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd. 2399-1 Mitarai, Nogi- machi, Shimotsuga- gun, Tochigi 329-01, Japan We conducted a fertility study on fleroxacin in Crj: Wistar rats. Fleroxacin was orally administered at doses of 20, 80 and 320 mg/ kg/ day to the male rats for 61 days before mating and until fertility was confirmed and to the females for 14 days before mating and up to the day 7 of gestation. 1. In the 320 mg/ kg male group, as general symptoms, an increase in unkempt fur was observed from the start of treatment. Sedation was also noted. 2. In the 320 mg/ kg male group, transient suppression of body weight gain was observed at the start of treatment, but afterwards, this was recovered. 3. In the 320 mg/ kg male group, the organ weight of epididymis and prostate significantly decreased. In histological findings of testes and epididymis, disappearance or reduction in spermatozoa and atrophy of seminiferous tubules were observed. 4. The mating performance of fleroxacin- treated groups was the same as that of the control group. 5. The number of implantations, the implantation rate and number of surviving fetuses significantly decreased in the 320 mg/ kg group, but no effect on growth or external defects in fetuses were observed. The maximum no- effect dose of fleroxacin was considered to be 80 mg/ kg for Fo rats and fetuses.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック